Scemblix Approved for Ph+ Chronic Myeloid Leukemia in Chronic Phase
Asciminib inhibits the ABL1 kinase activity of the BCRABL1 fusion protein, by binding to the ABL myristoyl pocket.
Diagnosis & Disease Information
Response-Based Ponatinib Dosing Appears Effective in Chronic Phase Chronic Myeloid Leukemia
A 45-mg starting dose, reduced to 15 mg, produced the best outcome.
Iclusig Approved for Resistant or Intolerant Chronic-Phase CML
The sNDA approval is based on efficacy and safety data from the open-label phase 2 OPTIC trial and 5-year data from the phase 2 PACE trial.
STAMP Inhibitor May Be a New Treatment Option in CML
Asciminib may be a new treatment option for patients with chronic myeloid leukemia in the chronic phase (CML-CP).
